Estados Unidos - inglés - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7) - acetaminophen 325 mg - hydrocodone bitartrate and acetaminophen tablets, usp are indicated for the management of moderate to moderately severe pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve hydrocodone bitartrate and acetaminophen tablets, usp for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): hydrocodone bitartrate and acetaminophen tablets, usp are contraindicated in patients with:

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - atorvastatin calcium trihydrate - film-coated tablet - 10 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - atorvastatin calcium trihydrate - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - atorvastatin calcium trihydrate - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - atorvastatin calcium trihydrate - film-coated tablet - 80 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Estados Unidos - inglés - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - clopidogrel tablets are indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non-st-segment elevation acs (unstable angina [ua]/non-st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel tablets should be administered in conjunction with aspirin. - clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel tablets should be administered in conjunction with aspirin. in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke. clopidogrel   tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel   tablets a

Estados Unidos - inglés - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - risedronate sodium hemi-pentahydrate (unii: hu2yaq274o) (risedronic acid - unii:km2z91756z) - risedronate sodium 5 mg - risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, risedronate sodium tablets reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1, 14.2) ]. risedronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis. risedronate sodium tablets are indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases. patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d. risedronate sodium tablets are indicated for treatment of paget's disease of bone in men and women. the optimal duration of use has not been determined. the safety and effectiveness

Estados Unidos - inglés - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - tetrabenazine (unii: z9o08yrn8o) (tetrabenazine - unii:z9o08yrn8o) - tetrabenazine 12.5 mg - tetrabenazine tablets are indicated for the treatment of chorea associated with huntington's disease. tetrabenazine is contraindicated in patients: - who are actively suicidal, or in patients with untreated or inadequately treated depression [see warnings and precautions (5.1)]. - with hepatic impairment [see use in specific populations (8.6), clinical pharmacology (12.3)]. - taking monoamine oxidase inhibitors (maois). tetrabenazine should not be used in combination with an maoi, or within a minimum of 14 days of discontinuing therapy with an maoi [see drug interactions (7.3)]. - taking reserpine. at least 20 days should elapse after stopping reserpine before starting tetrabenazine [see drug interactions (7.2)]. - taking deutetrabenazine or valbenazine [see drug interactions (7.7)]. risk summary there are no adequate data on the developmental risk associated with the use of tetrabenazine in pregnant women. administration of tetrabenazine to rats throughout pregnancy and lactation resulted in an increase in s